Last reviewed · How we verify

NCT03990376

Adolescent Idiopathic Scoliosis (AIS) Gold Standard for Blood Loss

Completed NA Last updated 11 June 2021
What this trial tests

NA trial testing Radioisotope I-131-labeled albumin in Adolescent Idiopathic Scoliosis in 30 participants. Completed in 10 September 2020.

Timeline
19 June 2019
Primary endpoint
10 September 2020
10 September 2020

Quick facts

Lead sponsorEmory University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment30
Start date19 June 2019
Primary completion10 September 2020
Estimated completion10 September 2020
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Emory University

Who can join

Adults 10 to 18, any sex, with Adolescent Idiopathic Scoliosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to establish a benchmark for measuring blood loss by directly measuring the change in red cell volume before and after surgery and to compare established blood loss estimators to this benchmark in order to determine the most accurate and precise method for estimating blood loss in adolescent idiopathic scoliosis surgery patients

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Adolescent Idiopathic Scoliosis

Currently open trials in the same condition.

Other Emory University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03990376.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing